Cardiac Sarcoidosis

Abstract

Sarcoidosis is a systemic disease which affects many organs, including the heart. Cardiac sarcoidosis has a reported incidence of about 25 % and carries a poor prognosis. It can occur in the form of conduction abnormalities, pericardial and valvular heart disease, congestive heart failure, arrhythmias and sudden cardiac death. The diagnosis of cardiac sarcoidosis is difficult, requiring a high index of suspicion and the use of electrocardiography, echocardiography, nuclear medicine imaging, myocardial biopsy and magnetic resonance imaging. Corticosteroids have been the cornerstone of treatment of cardiac sarcoidosis, but other immunosuppressives have also been used, along with standard heart failure therapy, antiarrhythmic medications, pacemakers and implantable defibrillators. Cardiac transplantation is an option for patients who do not respond to medical treatment. We briefly review the current armamentarium for the diagnosis and treatment of cardiac sarcoidosis.

Key words

cardiomyopathy - heart and lung transplantation - heart disease

References

• 1 James D G, Neville E, Carstairs L S. Bone and joint sarcoidosis.  Semin Arthritis Rheum. 1976;  6 53-81
• 2 Bernstein M, Konzelmann F W, Sidlick D M. Boeck's sarcoid: report of a case with visceral involvement.  Arch Int Med. 1929;  44 721-734
• 3 Silverman K J, Hutchins G M, Bulkley B H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.  Circulation. 1978;  58 1204-1211
• 4 Gozo E GJ, Cosnow I, Cohen H C, Okun L. The heart in sarcoidosis.  Chest. 1971;  60 379-388
• 5 Roberts W C, McAllister H AJ, Ferrans V J. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11).  Am J Med. 1977;  63 86-108
• 6 Desai M Y, Fallert M A. Rapidly progressing congestive heart failure due to cardiac sarcoidosis involving papillary muscles: a case report and brief review of the literature.  Cardiol Rev. 2003;  11 163-168
• 7 Shammas R L, Movahed A. Sarcoidosis of the heart.  Clin Cardiol. 1993;  16 462-472
• 8 Newman L, Rose C, Maier L. Sarcoidosis.  N Engl J Med. 1997;  336 1224-1234
• 9 Donsky A S, Escobar J, Capehart J, Roberts W C. Heart transplantation for undiagnosed cardiac sarcoidosis.  Am J Cardiol. 2002;  89 1447-1450
• 10 Flemming H, Bailey S. James DG Cardiac sarcoidosis. New York; Marcell Dekker 1994: 323-334
• 11 Lewin R F, Mor R, Spitzer S, Arditti A, Hellman C, Agmon J. Echocardiographic evaluation of patients with systemic sarcoidosis.  Am Heart J. 1985;  110 116-122
• 12 Sharma O. Diagnosis of cardiac sarcoidosis: an imperfect science, a hesitant art.  Chest. 2003;  123 18-19
• 13 Kinney E L, Jackson G L, Reeves W C, Zelis R. Thallium-scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction. An analysis of 44 patients.  Am J Med. 1980;  68 497-503
• 14 Fields C L, Ossorio M A, Roy T M, Denny D M, Varga D W. Thallium-201 scintigraphy in the diagnosis and management of myocardial sarcoidosis.  South Med J. 1990;  83 339-342
• 15 Tellier P, Paycha F, Antony I, Nitenberg A, Valeyre D, Foult J M. et al . Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis.  Am J Med. 1988;  85 189-193
• 16 Mañá J. Nuclear imaging. ⁶⁷Gallium, ²⁰¹thallium, ¹⁸F-labeled fluoro-2-deoxy-D-glucose positron emission tomography.  Clin Chest Med. 1997;  18 799-811
• 17 Kinney E L, Caldwell J W. Do thallium myocardial perfusion scan abnormalities predict survival in sarcoid patients without cardiac symptoms?.  Angiology. 1990;  41 573-576
• 18 Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis.  Chest. 1995;  107 330-334
• 19 Tajima T, Naito T, Dohi Y, Miyamae T. Ga-67 and Tl-201 imaging in sarcoidosis involving the myocardium.  Clin Nucl Med. 1981;  6 120-121
• 20 Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N. et al . Usefulness of fasting ¹⁸F‐FDG PET in identification of cardiac sarcoidosis.  J Nucl Med. 2004;  45 1989-1998
• 21 Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S. et al . Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study.  Chest. 2002;  122 1895-1901
• 22 Frank H, Globits S. Magnetic resonance imaging evaluation of myocardial and pericardial disease.  J Magn Reson Imaging. 1999;  10 617-626
• 23 Mahrholdt H, Wagner A, Judd R M, Sechtem U, Kim R J. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies.  Eur Heart J. 2005;  26 1461-1474
• 24 Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies.  Am Heart J. 1999;  138 299-302
• 25 Okura Y, Dec G W, Hare J M, Kodama M, Berry G J, Tazelaar H D. et al . A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis.  J Am Coll Cardiol. 2003;  41 322-329
• 26 Treaba D O, Benson M D, Assad L W, Dainauskas J R. Sarcoidosis and immunoglobulin lambda II light-chain amyloidosis diagnosed after orthotopic heart transplantation: a case report and review of the literature.  Mod Pathol. 2005;  18 451-455
• 27 Greif M, Petrakopoulou P, Weiss M, Reithmann C, Reichart B, Nabauer M. et al . Cardiac sarcoidosis concealed by arrhythmogenic right ventricular dysplasia/cardiomyopathy.  Nat Clin Pract Cardiovasc Med. 2008;  5 231-236
• 28 Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T. et al . Clinicopathological study of fatal myocardial sarcoidosis.  Ann NY Acad Sci. 1976;  278 455-469
• 29 Paz H L, McCormick D J, Kutalek S P, Patchefsky A. The automated implantable cardiac defibrillator. Prophylaxis in cardiac sarcoidosis.  Chest. 1994;  106 1603-1607
• 30 Ankersmit H J, Wieselthaler G A, Moser B, Taghavi S, Grimm M, Roth G. et al . Automated implantable cardiac defibrillator and biventricular Thoratec assist device as bridge to transplantation in a patient with sarcoidosis.  J Thorac Cardiovasc Surg. 2001;  121 1198-1199
• 31 Fasseas P, Galatro K M, Leybishkis B, Fyfe B. Cardiac involvement in sarcoidosis.  Tex Heart Inst J. 2001;  28 154-155
• 32 Valantine H A, Tazelaar H D, Macoviak J, Mullin A V, Hunt S A, Fowler M B. et al . Cardiac sarcoidosis: response to steroids and transplantation.  J Heart Transplant. 1987;  6 244-250
• 33 Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, Huong D LT. et al . Cardiac sarcoidosis: a retrospective study of 41 cases.  Medicine (Baltimore). 2004;  83 315-334
• 34 Oni A A, Hershberger R E, Norman D J, Ray J, Hovaguimian H, Cobanoglu A M. et al . Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids.  J Heart Lung Transplant. 1992;  11 367-369
• 35 Burke W M, Keogh A, Maloney P J, Delprado W, Bryant D H, Spratt P. Transmission of sarcoidosis via cardiac transplantation.  Lancet. 1990;  336 1579
• 36 Mitchell D N, Rees R J. A transmissible agent from sarcoid tissue.  Lancet. 1969;  2 81-84
• 37 Gokel J M, Reichart B, Struck E. Human cardiac transplantation–evaluation of morphological changes in serial endomyocardial biopsies.  Pathol Res Pract. 1985;  179 354-364
• 38 Ankersmit H J, Roth G, Zuckermann A, Moser B, Obermaier R, Taghavi S. et al . Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection.  Am J Transplant. 2003;  3 231-234